Loading clinical trials...
Loading clinical trials...
34 adult (\>18 years) cancer pain outpatients with Opioid base therapy because of pain and breakthrough pain or extreme pain on movement will be included in this prospective, randomized, double-blind crossover study. Over a period of 3 weeks patients will go through 3 treatment arms, each one lasting one week: Group A receives morphine drops and Placebo spray, Group B receives ketamine/chitosan spray nasal and Placebo drops and Group C receives morphine drops and ketamine/chitosan spray nasal. Primary endpoint is time to onset of action of intranasal ketamine compared with morphine drops. Secondary endpoint is the median numeric rating scale (NRS) improvement after using the spray or morphine or the combination of ketamine spray and morphine drops.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pain Relief Unit and Anaesthesiology, University Hospital Basel
Basel, Switzerland
Start Date
February 1, 2015
Primary Completion Date
July 1, 2017
Completion Date
July 6, 2017
Last Updated
November 13, 2018
11
ACTUAL participants
Morphine
DRUG
Ketamine
DRUG
Placebo
DRUG
Chitosan
DRUG
Lead Sponsor
University Hospital, Basel, Switzerland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions